Prior research has established some risk factors for an increased risk of severe disease and mortality from coronavirus disease 2019 (COVID-19). However, the impact of HIV infection on SARS-CoV-2 susceptibility and severity is a significant gap in the literature. In the same way, not many studies across the globe have analyzed the degree of vaccination willingness among people living with HIV/AIDS (PLWHA) and considerations regarding prioritizing this population during vaccination plans, particularly in developing countries.
Methods
A descriptive-analytical cross-sectional study was conducted. Self-completed electronic surveys directed to PLWHA were performed via Twitter in February 2021, using accounts of HIV activists.
Results
460 (87.1%) participants were willing to be vaccinated with any COVID-19 vaccine. The reasons for that were listed as 1) the belief that vaccination prevents both the COVID-19 infection (81.3%) as well as being a spreader (52.2%); 2) having a high occupational risk of becoming infected with COVID-19 (22%); and 3) the belief that they would be at high risk of death because of COVID-19 (21.3%). Only 56 (10.6%) participants expressed hesitancy toward vaccination, and 12 (2.2%) stated they did not want to get vaccinated.
Conclusions
Our results may support the prioritization of people living with HIV during the implementation of vaccination plans in developing countries. New strategies should be adopted to overcome the hesitancy and unwillingness toward the COVID-19 vaccination, especially in populations with risk factors for severe disease.
RazaiMSOsamaTMcKechnieDGJ, et al.Covid-19 vaccine hesitancy among ethnic minority groups. BMJ2021; 372: n513.
2.
DiazJVHerridgeMBertagnolioS, et al.Towards a universal understanding of post COVID-19 condition. Bull World Health Organ2021; 99(12): 901–903.
3.
J.H.U. United. States cases by county. Johns Hopkins University & MedicineJohns Hopkins University, Available from: https://coronavirus.jhu.edu/us-map.(2021, accessed 2 February 2022).
4.
AliIAliSIqbalS. COVID-19 vaccination: concerns about its accessibility, affordability, and acceptability. Front Med2021; 8.
5.
OehlerRLVegaVR. Conquering COVID: how global vaccine inequality risks prolonging the pandemic. Open Forum Infectious Diseases2021; 8: ofab443.
6.
PourcherVGourmelenJBureauI, et al.Comorbidities in people living with HIV: an epidemiologic and economic analysis using a claims database in France. Plos One2020; 15(12): e0243529.
7.
SarkarSBrownTT. Diabetes in people living with HIV, 2019. Endotext [Internet].
8.
YangJZhengYGouX, et al.Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis2020; 94: 91–95.
9.
MirzaeiHMcFarlandWKaramouzianM, et al.COVID-19 among people living with HIV: a systematic review. AIDS Behav2021; 25(1): 85–92.
10.
AlbercaRWOliveiraLMBrancoACCC, et al.Obesity as a risk factor for COVID-19: an overview. Crit Rev Food Sci Nutr2021; 61(13): 2262–2276.
11.
GoyalPChoiJJPinheiroLC, et al.Clinical characteristics of Covid-19 in New York city. N Engl J Med2020; 382(24): 2372–2374.
12.
GoyalPRingelJBRajanM, et al.Obesity and COVID-19 in New York city: a retrospective cohort study. Ann Intern Med2020; 173(10): 855–858.
13.
SharovKS. HIV/SARS-CoV-2 co-infection: T cell profile, cytokine dynamics and role of exhausted lymphocytes. Int J Infect Dis2021; 102: 163–169.
14.
HallAJosephODevlinS, et al.“That same stigma...that same hatred and negativity:” a qualitative study to understand stigma and medical mistrust experienced by people living with HIV diagnosed with COVID-19. BMC Infect Dis2021; 21(1): 1066–1068.
15.
NitpolprasertCAnandTPhanuphakN, et al.A qualitative study of the impact of coronavirus disease (COVID‐19) on psychological and financial wellbeing and engagement in care among men who have sex with men living with HIV in Thailand. HIV med2021; 23: 227.
16.
KalichmanSCEl-KrabR. Social and behavioral impacts of COVID-19 on people living with HIV: review of the irst year of research. Curr HIV/AIDS Rep2021; 19: 1–22.
17.
TesorieroJMSwainCEPierceJL, et al.COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state. JAMA Netw Open2021; 4(2): e2037069e2037069.
18.
Division of HIV Prevention N.C.f.H. Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention. 24/7: Saving Lives, Protecting PeopleTM. (n.d.) What to Know About HIV and COVID-19. Available from: https://www.cdc.gov/hiv/basics/covid-19.html. (Accesed 25 January 2022).
19.
BogartLMOjikutuOBTyagiK, et al.COVID-19 related medical mistrust, health impacts, and potential vaccine hesitancy among Black Americans living with HIV. J Acquir Immune Defic Syndr (1999) 2021; 86(2): 200.
20.
LaneSMacDonaldNEMartiM, et al.Vaccine hesitancy around the globe: analysis of three years of WHO/UNICEF joint reporting form data-2015-2017. Vaccine2018; 36(26): 3861–3867.
21.
WagnerALMastersNBDomekGJ, et al.Comparisons of vaccine hesitancy across five low- and middle-income countries. Vaccines2019; 7(4): 155.
22.
SallamM. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines (Basel)2021; 9(2): 160.
23.
KarlssonLCSoveriALewandowskyS, et al.Fearing the disease or the vaccine: the case of COVID-19. Pers Individ Dif2021; 172: 110590.
24.
OlagokeAAOlagokeOOHughesAM. Intention to vaccinate against the novel 2019 coronavirus disease: the role of health locus of control and religiosity. J Relig Health2021; 60(1): 65–80.
25.
PaulESteptoeAFancourtD. Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. Lancet Reg Health Eur2021; 1: 100012.
26.
YodaTKatsuyamaH. Willingness to receive COVID-19 vaccination in Japan. Vaccines (Basel)2021; 9(1): 48.
27.
Neumann-BöhmeSVargheseNESabatI, et al.Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur J Health Econ2020; 21: 977–982.
28.
HarrisonEAWuJW. Vaccine confidence in the time of COVID-19. Eur J Epidemiol2020; 35(4): 325–330.
29.
KranzerKLawnSDJohnsonLF, et al.Community viral load and CD4 count distribution among people living with HIV in a South African township: implications for treatment as prevention. J Acquir Immune Defic Syndr (1999) 2013; 63(4): 498–505.
30.
ValléeA.FournEMajerholcC, et al.COVID-19 vaccine hesitancy among French people living with HIV. Vaccines2021; 9(4): 302.
31.
MurphyJVallièresFBentallRP, et al.Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat Commun2021; 12(1): 1–15.
32.
SoaresPRochaJVMonizM, et al.Factors associated with COVID-19 vaccine hesitancy. Vaccines (Basel)2021; 9(3): 300.
33.
Solís ArceJSWarrenSSMeriggiNF, et al.COVID-19 vaccine acceptance and hesitancy in low-and middle-income countries. Nat Med2021; 27(8): 1385–1394.
MillsMRahalCBrazelD, et al.COVID-19 vaccine deployment: behaviour, ethics, misinformation and policy strategies. London: The Royal Society & The British Academy, 2020.
36.
TriantVALeeHHadiganC, et al.Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab2007; 92(7): 2506–2512.
37.
RuttenLJFZhuXLeppinAL, et al.Evidence-based strategies for clinical organizations to address COVID-19 vaccine hesitancy. Mayo Clin Proc2021; 96: 699.
38.
Urrunaga-PastorDBendezu-QuispeGHerrera-AñazcoP, et al.Cross-sectional analysis of COVID-19 vaccine intention, perceptions and hesitancy across Latin America and the Caribbean. Trav Med Infect Dis2021; 41: 102059.
39.
KellyBJSouthwellBGMcCormackLA, et al.Correction to: predictors of willingness to get a COVID-19 vaccine in the U.S. BMC Infect Dis2021; 21(1): 383–387.
40.
DormanCPereraACondonC, et al.Factors associated with willingness to be vaccinated against COVID-19 in a large convenience sample. J Commun Health2021; 46(5): 1013–1019.
41.
EarnshawVAEatonLAKalichmanSC, et al.COVID-19 conspiracy beliefs, health behaviors, and policy support. Transl Behav Med2020; 10(4): 850–856.
42.
MillerWRRoseGS. Toward a theory of motivational interviewing. Am Psychol2009; 64(6): 527–537.
43.
BogartLMMutchlerMGMcDavittB, et al.A randomized controlled trial of rise, a community-based culturally congruent adherence intervention for Black Americans living with HIV. Ann Behav Med2017; 51(6): 868–878.
44.
ShahidSMajeedMFAwaanAB, et al.Expanding access to HIV testing and counseling and exploring vulnerabilities among spouses of HIV-positive men who inject drugs in Pakistan. Curr Opin HIV AIDS2016; 11(Suppl 1): S6–S12.
45.
GreinacherAThieleTWarkentinTE, et al.Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med2021; 384(22): 2092–2101.
46.
SchultzNHSørvollIHMichelsenAE, et al.Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med2021; 384(22): 2124–2130.
